Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Primary Progressive Multiple Sclerosis Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Primary Progressive Multiple Sclerosis Treatmentmarket, defines the market attractiveness level of Primary Progressive Multiple Sclerosis Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Primary Progressive Multiple Sclerosis Treatment industry, describes the types of Primary Progressive Multiple Sclerosis Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Primary Progressive Multiple Sclerosis Treatment market and the development prospects and opportunities of Primary Progressive Multiple Sclerosis Treatment industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Primary Progressive Multiple Sclerosis Treatment market in Chapter 13.
By Player:
Glialogix, Inc
Teva Pharmaceutical Industries Ltd
Genzyme Corporation
F Hoffmann-La Roche Ltd
Santhera Pharmaceuticals Holding AG
MedDay SA
Kyorin Pharmaceutical Co, Ltd
By Type:
Biotin
GZ-402668
Ibudilast
Idebenone
Laquinimod Sodium
Others
By End-User:
Hospital
Clinic
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Primary Progressive Multiple Sclerosis Treatment Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Primary Progressive Multiple Sclerosis Treatment Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Primary Progressive Multiple Sclerosis Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Primary Progressive Multiple Sclerosis Treatment Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Primary Progressive Multiple Sclerosis Treatment Market Analysis and Outlook to 2022
-
7.1 Global Primary Progressive Multiple Sclerosis Treatment Consumption (2017-2022)
-
7.2 United States Primary Progressive Multiple Sclerosis Treatment Consumption (2017-2022)
-
7.3 Europe Primary Progressive Multiple Sclerosis Treatment Consumption (2017-2022)
-
7.4 China Primary Progressive Multiple Sclerosis Treatment Consumption (2017-2022)
-
7.5 Japan Primary Progressive Multiple Sclerosis Treatment Consumption (2017-2022)
-
7.6 India Primary Progressive Multiple Sclerosis Treatment Consumption (2017-2022)
-
7.7 South Korea Primary Progressive Multiple Sclerosis Treatment Consumption (2017-2022)
8 Region and Country-wise Primary Progressive Multiple Sclerosis Treatment Market Analysis and Outlook to 2028
-
8.1 Global Primary Progressive Multiple Sclerosis Treatment Consumption Forecast (2022-2028)
-
8.2 United States Primary Progressive Multiple Sclerosis Treatment Consumption Forecast (2022-2028)
-
8.3 Europe Primary Progressive Multiple Sclerosis Treatment Consumption Forecast (2022-2028)
-
8.4 China Primary Progressive Multiple Sclerosis Treatment Consumption Forecast (2022-2028)
-
8.5 Japan Primary Progressive Multiple Sclerosis Treatment Consumption Forecast (2022-2028)
-
8.6 India Primary Progressive Multiple Sclerosis Treatment Consumption Forecast (2022-2028)
-
8.7 South Korea Primary Progressive Multiple Sclerosis Treatment Consumption Forecast (2022-2028)
9 Global Primary Progressive Multiple Sclerosis Treatment Market Outlook by Types and Applications to 2022
-
9.1 Global Primary Progressive Multiple Sclerosis Treatment Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Biotin Consumption and Growth Rate (2017-2022)
-
9.1.2 Global GZ-402668 Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Ibudilast Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Idebenone Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Laquinimod Sodium Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Primary Progressive Multiple Sclerosis Treatment Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Global Primary Progressive Multiple Sclerosis Treatment Market Outlook by Types and Applications to 2028
-
10.1 Global Primary Progressive Multiple Sclerosis Treatment Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Biotin Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global GZ-402668 Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Ibudilast Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Idebenone Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Laquinimod Sodium Consumption Forecast and Growth Rate (2022-2028)
-
10.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Primary Progressive Multiple Sclerosis Treatment Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Primary Progressive Multiple Sclerosis Treatment Import and Export Analysis (Top 5 Countries)
-
11.1 Global Primary Progressive Multiple Sclerosis Treatment Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Primary Progressive Multiple Sclerosis Treatment Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Primary Progressive Multiple Sclerosis Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Primary Progressive Multiple Sclerosis Treatment Market Competitive Analysis
-
14.1 Glialogix, Inc
-
14.1.1 Glialogix, Inc Company Details
-
14.1.2 Glialogix, Inc Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Glialogix, Inc Primary Progressive Multiple Sclerosis Treatment Product and Service
-
14.2 Teva Pharmaceutical Industries Ltd
-
14.2.1 Teva Pharmaceutical Industries Ltd Company Details
-
14.2.2 Teva Pharmaceutical Industries Ltd Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Teva Pharmaceutical Industries Ltd Primary Progressive Multiple Sclerosis Treatment Product and Service
-
14.3 Genzyme Corporation
-
14.3.1 Genzyme Corporation Company Details
-
14.3.2 Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Product and Service
-
14.4 F Hoffmann-La Roche Ltd
-
14.4.1 F Hoffmann-La Roche Ltd Company Details
-
14.4.2 F Hoffmann-La Roche Ltd Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 F Hoffmann-La Roche Ltd Primary Progressive Multiple Sclerosis Treatment Product and Service
-
14.5 Santhera Pharmaceuticals Holding AG
-
14.5.1 Santhera Pharmaceuticals Holding AG Company Details
-
14.5.2 Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Product and Service
-
14.6 MedDay SA
-
14.6.1 MedDay SA Company Details
-
14.6.2 MedDay SA Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 MedDay SA Primary Progressive Multiple Sclerosis Treatment Product and Service
-
14.7 Kyorin Pharmaceutical Co, Ltd
-
14.7.1 Kyorin Pharmaceutical Co, Ltd Company Details
-
14.7.2 Kyorin Pharmaceutical Co, Ltd Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Kyorin Pharmaceutical Co, Ltd Primary Progressive Multiple Sclerosis Treatment Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Primary Progressive Multiple Sclerosis Treatment
-
Figure Primary Progressive Multiple Sclerosis Treatment Picture
-
Table Global Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Primary Progressive Multiple Sclerosis Treatment Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Primary Progressive Multiple Sclerosis Treatment Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Primary Progressive Multiple Sclerosis Treatment Consumption by Country (2017-2022)
-
Figure United States Primary Progressive Multiple Sclerosis Treatment Consumption and Growth Rate (2017-2022)
-
Table Europe Primary Progressive Multiple Sclerosis Treatment Consumption and Growth Rate (2017-2022)
-
Figure China Primary Progressive Multiple Sclerosis Treatment Consumption and Growth Rate (2017-2022)
-
Figure Japan Primary Progressive Multiple Sclerosis Treatment Consumption and Growth Rate (2017-2022)
-
Figure India Primary Progressive Multiple Sclerosis Treatment Consumption and Growth Rate (2017-2022)
-
Figure South Korea Primary Progressive Multiple Sclerosis Treatment Consumption and Growth Rate (2017-2022)
-
Figure Global Primary Progressive Multiple Sclerosis Treatment Consumption Forecast by Country (2022-2028)
-
Figure United States Primary Progressive Multiple Sclerosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Primary Progressive Multiple Sclerosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Primary Progressive Multiple Sclerosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Primary Progressive Multiple Sclerosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Primary Progressive Multiple Sclerosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Primary Progressive Multiple Sclerosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Biotin Consumption and Growth Rate (2017-2022)
-
Figure Global GZ-402668 Consumption and Growth Rate (2017-2022)
-
Figure Global Ibudilast Consumption and Growth Rate (2017-2022)
-
Figure Global Idebenone Consumption and Growth Rate (2017-2022)
-
Figure Global Laquinimod Sodium Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Biotin Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global GZ-402668 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ibudilast Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Idebenone Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Laquinimod Sodium Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Primary Progressive Multiple Sclerosis Treatment Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Primary Progressive Multiple Sclerosis Treatment Export by Region (Top 5 Countries) (2017-2028)
-
Table Glialogix, Inc (Foundation Year, Company Profile and etc.)
-
Table Glialogix, Inc Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Glialogix, Inc Primary Progressive Multiple Sclerosis Treatment Product and Service
-
Table Teva Pharmaceutical Industries Ltd (Foundation Year, Company Profile and etc.)
-
Table Teva Pharmaceutical Industries Ltd Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Industries Ltd Primary Progressive Multiple Sclerosis Treatment Product and Service
-
Table Genzyme Corporation (Foundation Year, Company Profile and etc.)
-
Table Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Product and Service
-
Table F Hoffmann-La Roche Ltd (Foundation Year, Company Profile and etc.)
-
Table F Hoffmann-La Roche Ltd Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table F Hoffmann-La Roche Ltd Primary Progressive Multiple Sclerosis Treatment Product and Service
-
Table Santhera Pharmaceuticals Holding AG (Foundation Year, Company Profile and etc.)
-
Table Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Product and Service
-
Table MedDay SA (Foundation Year, Company Profile and etc.)
-
Table MedDay SA Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table MedDay SA Primary Progressive Multiple Sclerosis Treatment Product and Service
-
Table Kyorin Pharmaceutical Co, Ltd (Foundation Year, Company Profile and etc.)
-
Table Kyorin Pharmaceutical Co, Ltd Primary Progressive Multiple Sclerosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Kyorin Pharmaceutical Co, Ltd Primary Progressive Multiple Sclerosis Treatment Product and Service
-
